| PM |
Report |
Q2 adjusted diluted EPS |
IN-LINE |
pred ~$2.08 vs. cons $2.07 |
MEDIUM |
| PM |
Report |
Q2 organic net revenue growth |
IN-LINE |
pred ~+5.5% vs. cons ~+5% |
MEDIUM |
| PM |
Report |
US ZYN shipment volume (cans) |
MISS |
pred ~178M cans vs. cons ~185M |
LOW |
| PM |
Guide |
FY2026 dollar adjusted diluted EPS |
UNCHANGED |
guide ~$8.31–8.46 vs. cons ~$8.40 (FY2026) |
MEDIUM |
| PM |
Guide |
FY2026 organic net revenue growth |
UNCHANGED |
guide +5% to +7% vs. cons ~+6% (FY2026) |
MEDIUM |
| PM |
Guide |
FY2026 currency-neutral adj. EPS growth |
UNCHANGED |
guide +7.5% to +9.5% vs. cons ~+9% (FY2026) |
MEDIUM |
| PM |
Guide |
H2 US ZYN offtake reacceleration commentary |
BETTER |
guide ~+20% vs. cons ~+15% (H2 2026) |
LOW |
| PM |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| PM |
Return |
5-day cumulative residual |
-2.0% (STABILIZE) |
Q2 is a self-flagged transition quarter (Japan pantry reversal, tough US ZYN comps, FX/RBH $0.33 charge) and the stock ran ~10% into the print (176→193) before fading to 188, so an in-line-to-cons EPS that only beats the FX-cut $1.97–2.02 guide triggers a modest sell-the-news day-1 dip led by soft ZYN shipments. But out-period math is supportive rather than punitive: the FY organic algo (+5–7% NR, +7–9% OI, +7.5–9.5% cn-EPS) should be reaffirmed, FX revisions are already known, and H2 carries easier comps plus the ULTRA/MRTP reaccel narrative — so estimates hold rather than get cut, and the quality-compounder bid stabilizes the stock near the day-1 level rather than following through lower. |
MEDIUM |